Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.33 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 5/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5185806 | 0.76 | PTGER4 (0.33) | PTGER4PTGER3PTGER2 | |
| SCHEMBL7286547 | 0.75 | PTGER4 (0.35) | PTGER4PTGER3PTGER2CTSL | |
| SCHEMBL9897850 | 0.71 | CTSK (0.40) | MEN1KMT2ALTA4HCTSKCTSL | |
| SCHEMBL16855279 | 0.71 | CTSK (0.40) | MEN1KMT2ALTA4HCTSKCTSL | |
| SCHEMBL1037969 | 0.71 | CTSK (0.40) | MEN1KMT2ALTA4HCTSKCTSL | |
| SCHEMBL6660560 | 0.71 | CTSK (0.40) | MEN1KMT2ALTA4HCTSKCTSL | |
| SCHEMBL9819752 | 0.71 | CTSK (0.40) | MEN1KMT2ALTA4HCTSKCTSL | |
| SCHEMBL13718823 | 0.71 | CTSK (0.40) | MEN1KMT2ALTA4HCTSKCTSL | |
| SCHEMBL7286099 | 0.70 | REN (0.39) | MEN1KMT2APTGER4PTGER3PTGER2 | |
| SCHEMBL9450427 | 0.70 | IDO1 (0.37) | PTGER4PTGER3PTGER2CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7232933-B2 | Lewis acid-catalysed aldehyde addition reaction on hydroxyalkynes followed by hydrogenation; preparing chiral 1,4-diols suitable for the preparation of chiral phospholane ligands for use in asymmetric catalysis. | JOHNSON MATTHEY PLC (GB) | 2007-06-19 | — | — | US | disclosed |
| US-20040143143-A1 | Lewis acid-catalysed aldehyde addition reaction on hydroxyalkynes followed by hydrogenation; preparing chiral 1,4-diols suitable for the preparation of chiral phospholane ligands for use in asymmetric catalysis. | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2004-07-22 | — | — | US | disclosed |
| EP-1389174-A1 | PREPARATION AND USE OF DIOLS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002094741-A1 | PREPARATION AND USE OF DIOLS | JOHNSON MATTHEY PLC (GB) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040143143-A1 | Lewis acid-catalysed aldehyde addition reaction on hydroxyalkynes followed by hydrogenation; preparing chiral 1,4-diols suitable for the preparation of chiral phospholane ligands for use in asymmetric catalysis. | ALDH3A1, GNPAT, HACL2 | MEN1 4038/4885KMT2A 1677/4885LTA4H 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.